Patents by Inventor Nicholas P. Restifo
Nicholas P. Restifo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10316289Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating nave T cells from a mammal, wherein the mammal is not a mouse; b) activating the nave T cells and expanding the numbers of nave T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: GrantFiled: September 6, 2012Date of Patent: June 11, 2019Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
-
Publication number: 20190060363Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: ApplicationFiled: November 6, 2018Publication date: February 28, 2019Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
-
Publication number: 20190060364Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: ApplicationFiled: November 6, 2018Publication date: February 28, 2019Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. Rosenberg, Douglas C. PALMER, Nicholas P. RESTIFO
-
Publication number: 20190054122Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: ApplicationFiled: November 5, 2018Publication date: February 21, 2019Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Publication number: 20190008899Abstract: Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.Type: ApplicationFiled: April 6, 2018Publication date: January 10, 2019Inventors: Branden MORIARITY, Beau WEBBER, Modassir CHOUDHRY, Steven A. ROSENBERG, Douglas C. PALMER, Nicholas P. RESTIFO
-
Patent number: 10166255Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.Type: GrantFiled: July 29, 2016Date of Patent: January 1, 2019Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, INTIMA BIOSCIENCE, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICESInventors: Branden Moriarity, Beau Webber, R. Scott McIvor, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
-
Publication number: 20170136063Abstract: Provided herein are methods for delaying or inhibiting T cell maturation or differentiation in vitro for a T cell therapy, comprising contacting one or more T cells from a subject in need of a T cell therapy with an AKT inhibitor and at least one of exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15), wherein the resulting T cells exhibit delayed maturation or differentiation. In some embodiments, the method further comprises administering the one or more T cells to a subject in need of a T cell therapy.Type: ApplicationFiled: October 20, 2016Publication date: May 18, 2017Applicants: Kite Pharma, Inc., National Cancer InstituteInventors: Arianne Perez, Marianna Sabatino, Steven A. Rosenberg, Nicholas P. Restifo
-
Patent number: 9522948Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: December 13, 2013Date of Patent: December 20, 2016Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20150299656Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: September 6, 2012Publication date: October 22, 2015Applicant: The United States of America, as represented by th Secretary, Department of Health and Human ServiceInventors: Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
-
Publication number: 20150275209Abstract: The invention provides an isolated or purified CD8+? T cell which comprises an antigen-specific T cell receptor and an exogenous nucleic acid encoding a microRNA-155 (miR-155) molecule, and methods of preparing the same. The invention also provides a pharmaceutical composition comprising the CD8+ T cell a carrier. Further provided is a method for treating or preventing a medical condition, such as cancer, by adoptively transferring to a mammal an amount of the CD8+? T cells effective to treat or prevent the medical condition.Type: ApplicationFiled: October 17, 2013Publication date: October 1, 2015Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServiceInventors: Yun Ji, Nicholas P. Restifo, Luca Gattinoni
-
Publication number: 20140219978Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: December 13, 2013Publication date: August 7, 2014Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8613932Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: May 30, 2012Date of Patent: December 24, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8556882Abstract: The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3? of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.Type: GrantFiled: April 22, 2010Date of Patent: October 15, 2013Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard A. Morgan, Steven A. Rosenberg, Ling Zhang, Nicholas P. Restifo
-
Publication number: 20120230962Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: May 30, 2012Publication date: September 13, 2012Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Patent number: 8216565Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: GrantFiled: January 11, 2008Date of Patent: July 10, 2012Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20120071859Abstract: The invention provides an isolated or purified nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12. The invention also provides a nucleic acid comprising a nucleotide sequence encoding a nuclear factor of activated T-cells (NFAT) promoter operatively associated with a nucleotide sequence encoding IL-12, wherein the NFAT promoter is located 3? of the nucleotide sequence encoding IL-12. Also provided are related recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. The invention further provides the use of the inventive nucleic acids or related materials in the treatment or prevention of cancer or an infectious disease in a mammal and in the induction of IL-12 expression in a mammal.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Richard A. Morgan, Steven A. Rosenberg, Ling Zhang, Nicholas P. Restifo
-
Patent number: 8012490Abstract: The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.Type: GrantFiled: September 22, 2009Date of Patent: September 6, 2011Assignees: Mount Sinai School of Medicine, The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Peter Palese, Adolfo Garcia-Sastre, Nicholas P. Restifo
-
Publication number: 20100080827Abstract: The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.Type: ApplicationFiled: September 22, 2009Publication date: April 1, 2010Inventors: PETER PALESE, ADOLFO GARCIA-SASTRE, NICHOLAS P. RESTIFO
-
Publication number: 20100015113Abstract: The invention provides human cells, particularly human T cells, comprising a murine T Cell Receptor (TCR) having antigen specificity for the cancer antigen gp100. Isolated or purified TCRs having antigenic specificity for amino acids 154-162 of gp100 (SEQ ID NO: 1), as well as related polypeptides, proteins, nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding fragments thereof, conjugates, and pharmaceutical compositions, are further provided. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host comprising the use of the inventive materials described herein.Type: ApplicationFiled: January 11, 2008Publication date: January 21, 2010Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Nicholas P. Restifo, Lydie Cassard, Zhiya Yu, Steven A. Rosenberg
-
Publication number: 20040253273Abstract: The present invention relates to the engineering of recombinant influenza viruses that express tumor-associated antigens. Expression of tumor-associated antigens by these viruses can be achieved by engineering specific epitopes into influenza virus proteins, or by engineering viral genes that encode a viral protein and the specific antigen as independent polypeptides. Tumor-bearing patients can be immunized with the recombinant influenza viruses alone, or in combination with another treatment, to induce an immune response that leads to tumor reduction. The recombinant viruses can also be used to vaccinate high risk tumor-free patients to prevent tumor formation in vivo.Type: ApplicationFiled: May 17, 2004Publication date: December 16, 2004Inventors: Peter Paleso, Adolfo Garcia-Sastre, Nicholas P. Restifo